Leandro Ferreyra-Garrot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leandro Ferreyra-Garrot has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Enrique Roberto Soriano
Hospital Italiano de Buenos Aires
6 shared publications Javier Rosa
Rheumatology Unit, Internal Medicine Department, Hospital Italiano de Buenos Aires, University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
3 shared publicationsJosefina Marin
From the Rheumatology Unit, Internal Medicine Department, and the Radiology Department, Hospital Italiano de Buenos Aires; University Institute Hospital Italiano de Buenos Aires; Fundación Dr. Pedro M. Catoggio para el Progreso de la Reumatología, Buenos Aires, Argentina
3 shared publicationsCarla Saucedo
2 shared publications- Diego Vila
Hospital Virgen del Carmen, Buenos Aires, Argentina
2 shared publications - Javier Rosa
Hospital Italiano de Buenos Aires
2 shared publications
Latest Publications
- 15 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7383-7390
Regional patterns of advanced therapy use and unmet disease control in axial spondyloarthritis across Latin America: a report from the ESPALDA-PANLAR registry
- 15 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7383-7390
Regional patterns of advanced therapy use and unmet disease control in axial spondyloarthritis across Latin America: a report from the ESPALDA-PANLAR registry
- 11 July 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5597-5610
Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review
The aim of this study was to develop a systematic review of quantitative studies focused on identifying factors associated with delay in diagnosing and treating adult patients with SLE. Electronic searches were conducted in Scopus, PubMed, and Web of Science for studies published up to 15 July 2024. Inclusion criteria were studies in adult patients that estimated delay in diagnosis and/or treatment, and associated barriers and facilitators. The Joanna Briggs Institute (JBI) Checklist was used to assess the quality of the studies. A total of 25 studies were included. The estimated median delay in diagnosis was 18 months [interquartile range (IQR) 0–32.3], and the time to treatment from diagnosis was 2.09 months (IQR 0.0–5.05). The median delay in diagnosis was 14.09 months (IQR 0.0–18.5) in men and 29.55 months (IQR 1.1–144.0) in women (n = 5). Early-onset SLE had a median delay of 3.88 months (IQR 1.5–9.1), while late-onset SLE had a median delay of 10.10 months (IQR 3.0–38.0) (n = 3). The barriers identified were the number of physicians consulted, misdiagnoses, lack of prompt access to a specialist, and lack of knowledge of the disease. The average quality of the studies was 6.4. The factors associated with diagnostic delay were being female, White, or of multiple races, having a less severe disease presentation, and older age. The reported median delays in the diagnosis and treatment of SLE are 18 months and 2.09 months, respectively. There is no consensus on defining diagnosis and/or treatment in SLE patients or a unified estimation method.
- 11 July 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5597-5610
Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review
The aim of this study was to develop a systematic review of quantitative studies focused on identifying factors associated with delay in diagnosing and treating adult patients with SLE. Electronic searches were conducted in Scopus, PubMed, and Web of Science for studies published up to 15 July 2024. Inclusion criteria were studies in adult patients that estimated delay in diagnosis and/or treatment, and associated barriers and facilitators. The Joanna Briggs Institute (JBI) Checklist was used to assess the quality of the studies. A total of 25 studies were included. The estimated median delay in diagnosis was 18 months [interquartile range (IQR) 0–32.3], and the time to treatment from diagnosis was 2.09 months (IQR 0.0–5.05). The median delay in diagnosis was 14.09 months (IQR 0.0–18.5) in men and 29.55 months (IQR 1.1–144.0) in women (n = 5). Early-onset SLE had a median delay of 3.88 months (IQR 1.5–9.1), while late-onset SLE had a median delay of 10.10 months (IQR 3.0–38.0) (n = 3). The barriers identified were the number of physicians consulted, misdiagnoses, lack of prompt access to a specialist, and lack of knowledge of the disease. The average quality of the studies was 6.4. The factors associated with diagnostic delay were being female, White, or of multiple races, having a less severe disease presentation, and older age. The reported median delays in the diagnosis and treatment of SLE are 18 months and 2.09 months, respectively. There is no consensus on defining diagnosis and/or treatment in SLE patients or a unified estimation method.
- 15 May 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Access, Effectiveness, Safety, and Survival of Secukinumab in Patients With Axial Spondyloarthritis and Axial Psoriatic Arthritis: A Real-World Study in Argentina
Objective: To describe the access, effectiveness, survival, and adverse events (AEs) of secukinumab (SEC) in patients with axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA).Methods: In a multicenter, observational, retrospective cohort study, patients ≥ 18 years with axSpA or axPsA who had received ≥ 1 dose of SEC were included. The number of days between the request for the drug and the first application was calculated. Effectiveness was defined as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) < 4 at 6 months. Drug survival was analyzed using Kaplan-Meier curves and Cox regression analysis.Results: One hundred seventeen patients were included: 72 (61.5%) with axPsA and 45 (38.5%) with axSpA. Those having public health insurance presented a longer delay in receiving SEC (median 90 days [IQR 60-150]) vs those using the social security system (P= 0.01) and those with private health coverage (P= 0.009). Effectiveness of SEC after 6 months was achieved in 72/117 patients (61.5%): 44/72 patients with axial PsA (61.5%) and 28/45 patients with axSpA (62.2%;P= 0.91). The median SEC survival was 48 months (95% CI 32-63). The only factor associated with reduced survival was SEC as third-line treatment or higher (hazard ratio 3.43, 95% CI 1.11-11.10;P= 0.04). The incidence of AEs was 7.9 events/100 patients/year (95% CI 5-12).Conclusion: The delay in receiving SEC was longer in patients with public health insurance. Patients using SEC as third-line or higher therapy had 3.4 times less survival. AEs were mild and no AEs of interest were observed.
- 15 May 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Access, Effectiveness, Safety, and Survival of Secukinumab in Patients With Axial Spondyloarthritis and Axial Psoriatic Arthritis: A Real-World Study in Argentina
Objective: To describe the access, effectiveness, survival, and adverse events (AEs) of secukinumab (SEC) in patients with axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA).Methods: In a multicenter, observational, retrospective cohort study, patients ≥ 18 years with axSpA or axPsA who had received ≥ 1 dose of SEC were included. The number of days between the request for the drug and the first application was calculated. Effectiveness was defined as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) < 4 at 6 months. Drug survival was analyzed using Kaplan-Meier curves and Cox regression analysis.Results: One hundred seventeen patients were included: 72 (61.5%) with axPsA and 45 (38.5%) with axSpA. Those having public health insurance presented a longer delay in receiving SEC (median 90 days [IQR 60-150]) vs those using the social security system (P= 0.01) and those with private health coverage (P= 0.009). Effectiveness of SEC after 6 months was achieved in 72/117 patients (61.5%): 44/72 patients with axial PsA (61.5%) and 28/45 patients with axSpA (62.2%;P= 0.91). The median SEC survival was 48 months (95% CI 32-63). The only factor associated with reduced survival was SEC as third-line treatment or higher (hazard ratio 3.43, 95% CI 1.11-11.10;P= 0.04). The incidence of AEs was 7.9 events/100 patients/year (95% CI 5-12).Conclusion: The delay in receiving SEC was longer in patients with public health insurance. Patients using SEC as third-line or higher therapy had 3.4 times less survival. AEs were mild and no AEs of interest were observed.
- 15 December 2018
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 46 (7) , 694-700
Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Low Back Pain
Objective.: To evaluate the diagnostic value of color Doppler ultrasound (CDUS) for the detection of sacroiliitis, in patients with inflammatory back pain (IBP).Methods.: Consecutive patients with IBP and suspected axial spondyloarthritis (SpA), but without a definitive diagnosis, were included. Consecutive patients with defined SpA and axial involvement were included as a control group. All patients underwent clinical evaluation, magnetic resonance imaging (MRI), and CDUS of sacroiliac joints (SIJ) within the same week. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the diagnosis of sacroiliitis by CDUS were calculated, using MRI as the gold standard.Results.: There were 198 SIJ evaluated in 99 patients (36 with previous SpA). There were 61 men (61.6%), with a mean age of 39.8 years (SD 11.3) and median disease duration of 24 months (IQR 12–84). At the patient level, CDUS had a sensitivity of 63% (95% CI 48.7–75.7%) and a specificity of 89% (95% CI 76–96%). The PPV was 87.2% (95% CI 72.6–95.7%) and the NPV was 66.7% (95% CI 53.3–78.3%). At joint level, CDUS had a sensitivity of 60% (95% CI 49–70%) and a specificity of 93% (95% CI 88–98%). The PPV was 83% (95% CI 78–95%) and the NPV was 43% (95% CI 33–56%). The sensitivity of CDUS for the diagnosis of axial SpA was 54% (95% CI 36.6–71.2%), specificity was 82% (95% CI 63.1–93.9%), PPV was 79% (95% CI 57.8–92.9%), and NPV was 59% (95% CI 42.1–74.4%).Conclusion.: CDUS showed adequate diagnostic properties for detection of sacroiliitis and is a useful tool in patients with IBP.
- 15 December 2018
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 46 (7) , 694-700
Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Low Back Pain
Objective.: To evaluate the diagnostic value of color Doppler ultrasound (CDUS) for the detection of sacroiliitis, in patients with inflammatory back pain (IBP).Methods.: Consecutive patients with IBP and suspected axial spondyloarthritis (SpA), but without a definitive diagnosis, were included. Consecutive patients with defined SpA and axial involvement were included as a control group. All patients underwent clinical evaluation, magnetic resonance imaging (MRI), and CDUS of sacroiliac joints (SIJ) within the same week. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the diagnosis of sacroiliitis by CDUS were calculated, using MRI as the gold standard.Results.: There were 198 SIJ evaluated in 99 patients (36 with previous SpA). There were 61 men (61.6%), with a mean age of 39.8 years (SD 11.3) and median disease duration of 24 months (IQR 12–84). At the patient level, CDUS had a sensitivity of 63% (95% CI 48.7–75.7%) and a specificity of 89% (95% CI 76–96%). The PPV was 87.2% (95% CI 72.6–95.7%) and the NPV was 66.7% (95% CI 53.3–78.3%). At joint level, CDUS had a sensitivity of 60% (95% CI 49–70%) and a specificity of 93% (95% CI 88–98%). The PPV was 83% (95% CI 78–95%) and the NPV was 43% (95% CI 33–56%). The sensitivity of CDUS for the diagnosis of axial SpA was 54% (95% CI 36.6–71.2%), specificity was 82% (95% CI 63.1–93.9%), PPV was 79% (95% CI 57.8–92.9%), and NPV was 59% (95% CI 42.1–74.4%).Conclusion.: CDUS showed adequate diagnostic properties for detection of sacroiliitis and is a useful tool in patients with IBP.
- 2 November 2017
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (12) , 2789-2797
Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries
Health education is fundamental in the management of RA patients. This study explored patient needs for educational material appropriate for RA patients in our region through a website. This study includes seven focus groups and semi-structured interviews across 4 countries (Argentina, Chile, Colombia, and Mexico) with 71 RA patients. Transcripts were analyzed by anthropologists using qualitative analysis (QA), resulting in themes and subthemes to be developed. Five themes and over 50 subthemes of interest were identified by patients. Grouped into categories as follows: (1) knowing the disease, (2) living with arthritis, (3) treatment and therapies for RA, (4) psychosocial support, and (5) information for families. A response was written by the team in plain Spanish on patient subthemes of interest including additional areas that the team considered relevant. Three videos for YouTube were produced: on patient-doctor relationships, patients at work, and home and at the clinic. Illustrations in a comic book format on RA diagnosis were created. The educational site on RA of PANLAR can be found at htpp://artritisreumatoide.cl. This project accomplished a comprehensive list of RA patient interests, revealing the complex relationship between the information on the disease, the experience of a chronic disease, and the way in which patients approach, conceive, and manage their disease. We expect to gather information on how the website will be used in the future for patients and their families and maintain and improve the website as well as adapt its content to different socioeconomic realities.
- 2 November 2017
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (12) , 2789-2797
Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries
Health education is fundamental in the management of RA patients. This study explored patient needs for educational material appropriate for RA patients in our region through a website. This study includes seven focus groups and semi-structured interviews across 4 countries (Argentina, Chile, Colombia, and Mexico) with 71 RA patients. Transcripts were analyzed by anthropologists using qualitative analysis (QA), resulting in themes and subthemes to be developed. Five themes and over 50 subthemes of interest were identified by patients. Grouped into categories as follows: (1) knowing the disease, (2) living with arthritis, (3) treatment and therapies for RA, (4) psychosocial support, and (5) information for families. A response was written by the team in plain Spanish on patient subthemes of interest including additional areas that the team considered relevant. Three videos for YouTube were produced: on patient-doctor relationships, patients at work, and home and at the clinic. Illustrations in a comic book format on RA diagnosis were created. The educational site on RA of PANLAR can be found at htpp://artritisreumatoide.cl. This project accomplished a comprehensive list of RA patient interests, revealing the complex relationship between the information on the disease, the experience of a chronic disease, and the way in which patients approach, conceive, and manage their disease. We expect to gather information on how the website will be used in the future for patients and their families and maintain and improve the website as well as adapt its content to different socioeconomic realities.
- 1 May 2017
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 44 (7) , 1018-1023
Utility of Power Doppler Ultrasound–detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission
Objective.: Power Doppler ultrasound (PDUS) has been shown to detect subclinical synovitis in psoriatic arthritis (PsA), but its value is not yet fully understood. The aim of this study was to evaluate PDUS features at joint level in patients with PsA in clinical remission and to investigate its value for predicting short-term flares.Methods.: Consecutive patients with PsA in clinical remission according to the attending rheumatologist and who fulfill minimal disease activity criteria and/or 28-joint Disease Activity Score in remission criteria underwent PDUS examination of 18 joints. All patients were followed up for 6 months. Disease flare was defined as any increase of disease activity generating the need of any of the following changes in therapy with disease-modifying antirheumatic drugs (DMARD) by the attending rheumatologist: dose increase, switch or addition of a different DMARD, and/or switch or addition of biological therapies.Results.: Among 54 patients with PsA in clinical remission, 15 (27.8%) experienced a flare within the next 6 months. Twenty patients had at least 1 joint with PDUS synovitis at baseline, and 13 (65%) of these had a disease flare during the followup period compared with only 2 of the 34 patients (5.9%) without baseline PDUS synovitis (relative risk = 11, 95% CI 2.8–44, p < 0.001). On logistic regression analysis, the only variables associated with short-term flares were baseline PDUS synovitis and the use of nonbiologic DMARD.Conclusion.: Among patients with PsA in clinical remission, PDUS-detected synovitis was a strong predictor of short-term flare of the disease.
- 1 May 2017
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 44 (7) , 1018-1023
Utility of Power Doppler Ultrasound–detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission
Objective.: Power Doppler ultrasound (PDUS) has been shown to detect subclinical synovitis in psoriatic arthritis (PsA), but its value is not yet fully understood. The aim of this study was to evaluate PDUS features at joint level in patients with PsA in clinical remission and to investigate its value for predicting short-term flares.Methods.: Consecutive patients with PsA in clinical remission according to the attending rheumatologist and who fulfill minimal disease activity criteria and/or 28-joint Disease Activity Score in remission criteria underwent PDUS examination of 18 joints. All patients were followed up for 6 months. Disease flare was defined as any increase of disease activity generating the need of any of the following changes in therapy with disease-modifying antirheumatic drugs (DMARD) by the attending rheumatologist: dose increase, switch or addition of a different DMARD, and/or switch or addition of biological therapies.Results.: Among 54 patients with PsA in clinical remission, 15 (27.8%) experienced a flare within the next 6 months. Twenty patients had at least 1 joint with PDUS synovitis at baseline, and 13 (65%) of these had a disease flare during the followup period compared with only 2 of the 34 patients (5.9%) without baseline PDUS synovitis (relative risk = 11, 95% CI 2.8–44, p < 0.001). On logistic regression analysis, the only variables associated with short-term flares were baseline PDUS synovitis and the use of nonbiologic DMARD.Conclusion.: Among patients with PsA in clinical remission, PDUS-detected synovitis was a strong predictor of short-term flare of the disease.
- 1 March 2016
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 43 (5) , 907-910
Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin
Objective To evaluate components of the minimal disease activity (MDA) criteria in psoriatic arthritis (PsA). Methods In patients achieving and not achieving MDA, fulfillment of each of the 7 criteria was evaluated. Results Among 41 patients with MDA, 7.4% did not fulfill the tender/swollen joint count whereas 49% did not fulfill the skin criteria. Of the 42 patients not fulfilling MDA, 100%, 76.5%, and 65% did not fulfill the patient pain score, the patient’s global assessment, and the Psoriasis Area and Severity Index (PASI), respectively. Conclusion A minority of patients with PsA fulfilling the MDA criteria presented active joints, but half had active skin. Visual analog scale scores and the PASI prevented patients from achieving MDA.
- 1 March 2016
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 43 (5) , 907-910
Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin
Objective To evaluate components of the minimal disease activity (MDA) criteria in psoriatic arthritis (PsA). Methods In patients achieving and not achieving MDA, fulfillment of each of the 7 criteria was evaluated. Results Among 41 patients with MDA, 7.4% did not fulfill the tender/swollen joint count whereas 49% did not fulfill the skin criteria. Of the 42 patients not fulfilling MDA, 100%, 76.5%, and 65% did not fulfill the patient pain score, the patient’s global assessment, and the Psoriasis Area and Severity Index (PASI), respectively. Conclusion A minority of patients with PsA fulfilling the MDA criteria presented active joints, but half had active skin. Visual analog scale scores and the PASI prevented patients from achieving MDA.
- 13 May 2014
- Published by Springer Nature in Clinical Rheumatology
- Vol. 33 (9) , 1323-1330
Remission criteria and activity indices in psoriatic arthritis
Remission criteria and activity indices used in rheumatoid arthritis (RA) are often applied in psoriatic arthritis (PsA). Some new indices have been specifically developed for PsA. Our objective was to evaluate the performance of different remission criteria and activity indices in PsA. This is a cross-sectional study that includes consecutive patients with PsA. Information necessary to complete the following indices was captured: Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Screening and Evaluation (PASE), Disease Activity Index for Psoriatic Arthritis (DAPSA), Disease Activity Score in 28 Joints (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) Boolean RA remission criteria. Patients were classified according to activity categories (remission, low, medium, or high disease activity). Correlation between indices was established. Fifty-five patients were included. Mean age was 53 years (SD = 12), and 35 (63.6 %) were males. Mean PsA disease duration was 5.9 years (SD = 8.5), and mean psoriasis duration was 15.9 (SD = 12.6). We found important differences in the percentage of patients classified as in remission by applying different remission criteria: DAS28 = 33 % (95 % confidence interval (CI) 20–45) vs ACR/EULAR = 4 % (95 % CI 1–17). Particularly, DAS28 and minimal disease activity seemed to be less stringent in PsA than the other indices. Of the specific PsA indices evaluated, CPDAI showed the poorest correlation with all the other activity measurements, although differences were not statistically significant in most cases. Disease activity in PsA is measured by many different indices. In spite they all showed good correlations between them, they classified different patients in different disease status.
- 13 May 2014
- Published by Springer Nature in Clinical Rheumatology
- Vol. 33 (9) , 1323-1330
Remission criteria and activity indices in psoriatic arthritis
Remission criteria and activity indices used in rheumatoid arthritis (RA) are often applied in psoriatic arthritis (PsA). Some new indices have been specifically developed for PsA. Our objective was to evaluate the performance of different remission criteria and activity indices in PsA. This is a cross-sectional study that includes consecutive patients with PsA. Information necessary to complete the following indices was captured: Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Screening and Evaluation (PASE), Disease Activity Index for Psoriatic Arthritis (DAPSA), Disease Activity Score in 28 Joints (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) Boolean RA remission criteria. Patients were classified according to activity categories (remission, low, medium, or high disease activity). Correlation between indices was established. Fifty-five patients were included. Mean age was 53 years (SD = 12), and 35 (63.6 %) were males. Mean PsA disease duration was 5.9 years (SD = 8.5), and mean psoriasis duration was 15.9 (SD = 12.6). We found important differences in the percentage of patients classified as in remission by applying different remission criteria: DAS28 = 33 % (95 % confidence interval (CI) 20–45) vs ACR/EULAR = 4 % (95 % CI 1–17). Particularly, DAS28 and minimal disease activity seemed to be less stringent in PsA than the other indices. Of the specific PsA indices evaluated, CPDAI showed the poorest correlation with all the other activity measurements, although differences were not statistically significant in most cases. Disease activity in PsA is measured by many different indices. In spite they all showed good correlations between them, they classified different patients in different disease status.
- 1 September 2013
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 19 (6) , 303-307
Incidence and Prevalence of Polymyositis and Dermatomyositis in a Health Management Organization in Buenos Aires
Polymyositis (PM) and dermatomyositis (DM) are infrequent diseases. Data on incidence and prevalence are scarce and conflicting. There are no such data in Latin America and in Argentina in particular. We undertook to examine the incidence and prevalence of PM/DM in the prepaid health maintenance organization (HMO) of our hospital, in the city of Buenos Aires. Members of the HMO between January 1999 and June 2009 were identified from medical records of patients followed up by us at the HMO. Incident cases and prevalence were calculated at the end of the period. During the study period, 146,747 persons contributed a total of 937,902.6 person-years (mean age was 46.6 [SD, 18.4] years, and 59% were female). Ten incident cases were detected, 7 women and 3 men with a global incidence rate (IR) of 1.07 per 100,000 person-years (95% confidence interval [CI], 0.5-1.84). Three subjects had DM with an IR of 0.32 per 100,000 person-years (95% CI, 0.1-0.99), and 7 had PM with an IR of 0.75 per 100,000 person-years (95% CI, 0.35-0.16). On June 1, 2009, 17 prevalent cases were detected, with a mean age of 48.9 (SD, 17.7) years; 76% were female, representing a prevalence of 17.4 per 100,000 persons (95% CI, 10.1-27.8). Among the 17 patients with idiopathic inflammatory myopathy, 10 patients had DM, with a prevalence of 10.22 per 100,000 persons (95% CI, 4.9-18.8), and 7 had PM (prevalence, 7.2 per 100,000 persons [95% CI, 2.9-14.7]). It is difficult to compare studies from different populations and using different ascertainment techniques. These first data from Latin America are in general agreement with many studies.
- 1 September 2013
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 19 (6) , 303-307
Incidence and Prevalence of Polymyositis and Dermatomyositis in a Health Management Organization in Buenos Aires
Polymyositis (PM) and dermatomyositis (DM) are infrequent diseases. Data on incidence and prevalence are scarce and conflicting. There are no such data in Latin America and in Argentina in particular. We undertook to examine the incidence and prevalence of PM/DM in the prepaid health maintenance organization (HMO) of our hospital, in the city of Buenos Aires. Members of the HMO between January 1999 and June 2009 were identified from medical records of patients followed up by us at the HMO. Incident cases and prevalence were calculated at the end of the period. During the study period, 146,747 persons contributed a total of 937,902.6 person-years (mean age was 46.6 [SD, 18.4] years, and 59% were female). Ten incident cases were detected, 7 women and 3 men with a global incidence rate (IR) of 1.07 per 100,000 person-years (95% confidence interval [CI], 0.5-1.84). Three subjects had DM with an IR of 0.32 per 100,000 person-years (95% CI, 0.1-0.99), and 7 had PM with an IR of 0.75 per 100,000 person-years (95% CI, 0.35-0.16). On June 1, 2009, 17 prevalent cases were detected, with a mean age of 48.9 (SD, 17.7) years; 76% were female, representing a prevalence of 17.4 per 100,000 persons (95% CI, 10.1-27.8). Among the 17 patients with idiopathic inflammatory myopathy, 10 patients had DM, with a prevalence of 10.22 per 100,000 persons (95% CI, 4.9-18.8), and 7 had PM (prevalence, 7.2 per 100,000 persons [95% CI, 2.9-14.7]). It is difficult to compare studies from different populations and using different ascertainment techniques. These first data from Latin America are in general agreement with many studies.